Thendor Therapeutics
Thendor Therapeutics is an early-stage biotechnology company focused on developing therapies aimed at reversing, halting, and preventing fibrosis across multiple organ systems. Leveraging peptide-based drug discovery, the company's mission is to restore tissue function and improve patient outcomes in pulmonary, urological, and systemic fibrotic diseases. Through a combination of targeted pathway research, regenerative approaches, and platform innovation, Thendor Therapeutics seeks to address unmet needs in fibrotic disease, which currently lacks effective treatments.
Industries
N/A
Expertise Areas
- Fibrosis drug discovery
- Pulmonary fibrosis research
- Urological fibrosis research
- Systemic and multi-organ fibrotic disease
Key Technologies
- Peptide therapeutics
- Targeted drug delivery
- Biomarker analysis (e.g. lysyl oxidase)
- Pathway-specific molecular targeting
Key People
Scientific Founder, Acting CSO
Co-Founder, CEO
Co-Founder, CFO
Senior VP, Technical Operations
VP, Intellectual Property
Scientific Founder, Acting CSO
Co-Founder, CEO
Co-Founder, CFO
Senior VP, Technical Operations
VP, Intellectual Property
News & Updates
Awarded to Dr. Carol Feghali-Bostwick for outstanding contributions to scleroderma research and innovative antifibrotic treatment advancement.
Dr. Carol Feghali-Bostwick selected as an innovator to showcase antifibrotic technology on Capitol Hill for Women's History Month.
Study shows scleroderma patients with lung fibrosis exhibit reduced antifibrotic protein Cathepsin L, identifying new therapeutic targets.
Mechanistic study identifies how the E4 peptide reverses fibrosis across multiple organs, activating the urokinase pathway.
Identifies lysyl oxidase as a potential biomarker for fibrosis progression and treatment monitoring in scleroderma.
Awarded to Dr. Carol Feghali-Bostwick for outstanding contributions to scleroderma research and innovative antifibrotic treatment advancement.
Dr. Carol Feghali-Bostwick selected as an innovator to showcase antifibrotic technology on Capitol Hill for Women's History Month.
Study shows scleroderma patients with lung fibrosis exhibit reduced antifibrotic protein Cathepsin L, identifying new therapeutic targets.
Mechanistic study identifies how the E4 peptide reverses fibrosis across multiple organs, activating the urokinase pathway.
Identifies lysyl oxidase as a potential biomarker for fibrosis progression and treatment monitoring in scleroderma.